The role of endothelium and endogenous vasoactive substances in sepsis

Hippokratia

Volumn 14, Issue 2, 2010, Pages 88-93

  Kotsovolis, G ^a   Kallaras, K ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Endothelin; Endothelium; Natriuretic peptides; Nitric oxide; Ssepsis; Vasoasctive substances

Indexed keywords

ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN; ENDOTHELIN 1; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; PROSTACYCLIN; VASOACTIVE AGENT; VASOPRESSIN;

BLOOD CLOTTING DISORDER; BLOOD VESSEL TONE; CARDIOVASCULAR SYSTEM; CELL ACTIVATION; CELL MEMBRANE PERMEABILITY; CRITICALLY ILL PATIENT; CYTOKINE RELEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPOTENSION; LABORATORY TEST; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

EID: 77950790392     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Angus DC, Pereira CA, Silva E. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets. 2006; 6: 207-212.
2. Morgan EG, Mikhail MS, Murray MJ. Critical care. In: Clinical Anesthesiology. 4th ed. New York: McGraw-Hill; 2006. p. 1049-1057.
3. Witthaut R. Science review: Natriuretic peptides in critical illness. Crit Care. 2004; 8: 342-349.
4. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003; 31: 1250-1256.
5. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003; 101: 3765-3777.
6. Sunden-Cullberg J, Norrby-Teglund A, Treutiger CJ. The role of high mobility group box-1 protein in severe sepsis. Curr Opin Infect Dis. 2006; 19: 231-236.
7. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993; 328: 1471-1477.
8. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 2006; 113: 227-242.
9. Yasuda S, Lew WY. Lipopolysaccharide depresses cardiac contractility and beta-adrenergic contractile response by decreasing myofilament response to Ca2+ in cardiac myocytes. Circ Res. 1997; 81: 1011-1020.
10. Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA. Left ventricular systolic and diastolic function in septic shock. Intensive Care Med. 1997; 23: 553-560.
11. Gerritsen ME. Functional heterogeneity of vascular endothelial cells. Biochem Pharmacol. 1987; 36: 2701-2711.
12. Galley HF, Webster NR. Physiology of the endothelium. Br J Anaesth. 2004; 93: 105-113.
13. Zardi EM, Zardi DM, Cacciapaglia F, Dobrina A, Amoroso A, Picardi A, et al. Endothelial dysfunction and activation as an expression of disease: Role of prostacyclin analogs. Int Immunopharmacol. 2005; 5: 437-459.
14. Zardi EM, Zardi DM, Dobrina A, Afeltra A. Prostacyclin in sepsis: A systematic review. Prostaglandins Other Lipid Mediat. 2007; 83: 1-24.
15. Reidy MA, Schwartz SM. Endothelial injury and regeneration. IV. endotoxin: A nondenuding injury to aortic endothelium. Lab Invest. 1983; 48: 25-34.
16. Vallet B. Bench-to-bedside review: Endothelial cell dysfunction in severe sepsis: A role in organ dysfunction? Crit Care. 2003; 7: 130-138.
17. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006; 6: 813-822.
18. Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000; 157: 1415-1430.
19. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986; 163: 740-745.
20. Schleef RR, Loskutoff DJ. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis. 1988; 18: 328-341.
21. Chandra A, Enkhbaatar P, Nakano Y, Traber LD, Traber DL. Sepsis: Emerging role of nitric oxide and selectins. Clinics. 2006; 61: 71-76.
22. Yi ES, Ulich TR. Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol. 1992; 140: 659-663.
23. Cuschieri J, Gourlay D, Garcia I, Jelacic S, Maier RV. Modulation of endotoxin-induced endothelial function by calcium/calmodulin-dependent protein kinase. Shock. 2003; 20: 176-182.
24. Huet O, Obata R, Aubron C, Spraul-Davit A, Charpentier J, Laplace C, et al. Plasma-induced endothelial oxidative stress is related to the severity of septic shock. Crit Care Med. 2007; 35: 821-826.
25. Tiruppathi C, Naqvi T, Sandoval R, Mehta D, Malik AB. Synergistic effects of tumor necrosis factor-alpha and thrombin in increasing endothelial permeability. Am J Physiol Lung Cell Mol Physiol. 2001; 281: 958-968.
26. Marx G. Fluid therapy in sepsis with capillary leakage. Eur J Anaesthesiol. 2003; 20: 429-442.
27. Groeneveld AB, Verheij J. Extravascular lung water to blood volume ratios as measures of permeability in sepsis-induced ALI/ARDS. Intensive Care Med. 2006; 32: 1315-1321.
28. McCuskey RS, Urbaschek R, Urbaschek B. The microcirculation during endotoxemia. Cardiovasc Res. 1996; 32: 752-763.
29. Sayk F, Vietheer A, Schaaf B, Wellhoener P, Weitz G, Lehnert H, et al. Endotoxemia causes central downregulation of sympathetic vasomotor tone in healthy humans. Am J Physiol Regul Integr Comp Physiol. 2008; 295: 891-898.
30. Chernow B, Rainey TG, Lake CR. Endogenous and exogenous catecholamines in critical care medicine. Crit Care Med. 1982; 10: 409-416.
31. McGill SN, Ahmed NA, Christou NV. Endothelial cells: Role in infection and inflammation. World J Surg. 1998; 22: 171-178.
32. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987; 84: 9265-9269.
33. Ignarro LJ. Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol. 1991; 41: 485-490.
34. Parratt JR. Nitric oxide in sepsis and endotoxaemia. J Antimicrob Chemother. 1998; 41: 31-39.
35. Kirkeboen KA, Strand OA. The role of nitric oxide in sepsis--an overview. Acta Anaesthesiol Scand. 1999; 43: 275-288.
36. Calver A, Collier J, Vallance P. Nitric oxide and cardiovascular control. Exp Physiol. 1993; 78: 303-326.
37. Davies PF, Barbee KA, Volin MV, Robotewskyj A, Chen J, Joseph L, et al. Spatial relationships in early signaling events of flow-mediated endothelial mechanotransduction. Annu Rev Physiol. 1997; 59: 527-549.
38. Radomski MW, Palmer RM, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-1489.
39. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991; 88: 4651-4655.
40. Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest. 1992; 90: 1116-1121.
41. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994; 269: 13725-13728.
42. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol. 1990; 259: 1038-1043.
43. Bogle RG, MacAllister RJ, Whitley GS, Vallance P. Induction of NG-monomethyl-L-arginine uptake: A mechanism for differential inhibition of NO synthases? Am J Physiol 1995; 269: 750-756.
44. Kumar A, Brar R, Wang P, Dee L, Skorupa G, Khadour F, et al. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol. 1999; 276: 265-276.
45. Watson D, Grover R, Anzueto A, Lorente J, Smithies M, Bellomo R, et al. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004; 32: 13-20.
46. Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004; 32: 1-12.
47. Ogawa Y, Nakao K, Mukoyama M, Hosoda K, Shirakami G, Arai H, et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. the ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res. 1991; 69: 491-500.
48. Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmidt-Schweda S, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length. Circulation. 2000; 102: 3074-3079.
49. Phua J, Lim TK, Lee KH. B-type natriuretic peptide: Issues for the intensivist and pulmonologist. Crit Care Med. 2005; 33: 2094-2113.
50. Chen HH, Burnett JC,Jr. C-type natriuretic peptide: The endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol. 1998; 32: 22-28.
51. Witthaut R, Busch C, Fraunberger P, Walli A, Seidel D, Pilz G, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 2004; 29: 1696-1702.
52. Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med. 2006; 34: 2140-2144.
53. Rackow EC, Kaufman BS, Falk JL, Astiz ME, Weil MH. Hemodynamic response to fluid repletion in patients with septic shock: Evidence for early depression of cardiac performance. Circ. 1987; 22: 11-22.
54. Januzzi JL, Morss A, Tung R, Pino R, Fifer MA, Thompson BT, et al. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: A prospective cohort study. Crit Care. 2006; 10: 37.
55. Forfia PR, Watkins SP, Rame JE, Stewart KJ, Shapiro EP. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol. 2005; 45: 1667-1671.
56. Court O, Kumar A, Parrillo JE, Kumar A. Clinical review: Myocardial depression in sepsis and septic shock. Crit Care. 2002; 6: 500-508.
57. Wolff B, Haase D, Lazarus P, Machill K, Graf B, Lestin HG, et al. Severe septic inflammation as a strong stimulus of myocardial NT-pro brain natriuretic peptide release. Int J Cardiol. 2007; 122: 131-136.
58. Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettila V. FINN-SEPSIS Study Group. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med. 2007; 35: 1277-1283.
59. Chiurchiu V, Izzi V, D'Aquilio F, Carotenuto F, Di Nardo P, Baldini PM. Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept. 2008; 148: 26-32.
60. Almog Y, Novack V, Megralishvili R, Kobal S, Barski L, King D, et al. Plasma level of N terminal pro-brain natriuretic peptide as a prognostic marker in critically ill patients. Anesth Analg. 2006; 102: 1809-1815.
61. Hoffmann U, Brueckmann M, Bertsch T, Wiessner M, Liebetrau C, Lang S, et al. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Clin Lab. 2005; 51: 373-379.
62. Roch A, Allardet-Servent J, Michelet P, Oddoze C, Forel JM, Barrau K, et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med. 2005; 33: 1001-1007.
63. Bhalla V, Bhalla MA, Maisel AS. Evolution of B-type natriuretic peptide in evaluation of intensive care unit shock. Crit Care Med. 2004; 32: 1787-1789.
64. Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med. 2004; 32: 660-665.
65. Tang BM, Huang SJ, Seppelt I, McLean AS. Predictive value of N-terminal pro-brain natriuretic peptide in sepsis. Crit Care Med. 2007; 35: 2464.
66. McLean AS, Huang SJ, Hyams S, Poh G, Nalos M, Pandit R, et al. Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock. Crit Care Med. 2007; 35: 1019-1026.
67. Mekontso-Dessap A, de Prost N, Girou E, Braconnier F, Lemaire F, Brun-Buisson C, et al. B-type natriuretic peptide and weaning from mechanical ventilation. Intensive Care Med. 2006; 32: 1529-1536.
68. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411-415.
69. Wanecek M, Weitzberg E, Rudehill A, Oldner A. The endothelin system in septic and endotoxin shock. Eur J Pharmacol. 2000; 407: 1-15.
70. Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994; 46: 325-415.
71. Arai H, Nakao K, Hosoda K, Ogawa Y, Nakagawa O, Komatsu Y, et al. Molecular cloning of human endothelin receptors and their expression in vascular endothelial cells and smooth muscle cells. Jpn Circ J. 1992; 56: 1303-1307.
72. Voerman HJ, Stehouwer CD, van Kamp GJ, Strack van Schijndel RJ, Groeneveld AB, Thijs LG. Plasma endothelin levels are increased during septic shock. Crit Care Med. 1992; 20: 1097-1101.
73. Pittet JF, Morel DR, Hemsen A, Gunning K, Lacroix JS, Suter PM, et al. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg. 1991; 213: 261-264.
74. Wanecek M, Weitzberg E, Alving K, Rudehill A, Oldner A. Effects of the endothelin receptor antagonist bosentan on cardiac performance during porcine endotoxin shock. Acta Anaesthesiol. 2001; 45: 1262-1270.
75. Wanecek M, Oldner A, Rudehill A, Sollevi A, Alving K, Weitzberg E. Endothelin(A)-receptor antagonism attenuates pulmonary hypertension in porcine endotoxin shock. Eur Respir J. 1999; 13: 145-151.
76. Nord EP. Role of endothelin in acute renal failure. Blood Purif. 1997; 15: 273-285.
77. Schulz E, Ruschitzka F, Lueders S, Heydenbluth R, Schrader J, Muller GA. Effects of endothelin on hemodynamics, prostaglandins, blood coagulation and renal function. Kidney Int. 1995; 47: 795-801.
78. Oldner A, Wanecek M, Weitzberg E, Sundin P, Sollevi A, Rubio C, et al. Differentiated effects on splanchnic homeostasis by selective and non-selective endothelin receptor antagonism in porcine endotoxaemia. Br J Pharmacol. 1999; 127: 1793-1804.